Abstract:ABSTRACT Background This study is for KRAS wildtype patients with unresectable liver only metastasis of colorectal cancer, using cetuximab + modified FOLFOX-6 as first-line chemotherapy, to observe whether the addition of targeted drug further increases the curative resection rate and improves long-term survival for patients. Methods Up to May 1st,a total of 82 KRAS wild-type patients enrolled and received cetuximab (500 mg/m2 q2w)Plus mFOLFOX-6 including oxaliplatin 85 mg/m2 plus CF 400 mg/m2 and 5-FU as a 400 mg/m2 bolus followed by 2400 mg/m2 infusion over 46 hours on day 1, repeated every 2 weeks for maximum of nine cycles. The primary endpoint was R0 resection rate. Findings The objective response rate (RR) was 81.82% ± 5.81% among 44 patients with efficacy assessment. Among 38 cases went through surgical evaluation (finished medication), 16 cases went through R0 resection and R0 resection rate was 42.11% ± 8.01%, 4 cases went through R1 resection and R1 resection rate was 10.53% ± 4.98%, and 4 cases went through R0 + RFA. There were AEs reported in 64 cases, mainly including rash and malaise. One SAE was reported and the subject was withdrawn due to allergy. Interpretation Cetuximab + mFOLFOX-6 was well tolerated and provided good RR, R0 resection rates, which would be potentially used as a first-line treatment for patients with unresectable liver only metastasis of colorectal cancer. Funding: This study was supported by Fudan University Shanghai Cancer Center; Merck KGaA Darmstadt, Germany. Funding This study was supported by Merck KGaA Darmstadt, Germany and Sanofi-aventis. Disclosure All authors have declared no conflicts of interest.

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial